CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Iron chelators ICL670 and 311 inhibit HIV-1 transcription
Authors
Tatyana Ammosova
Sharroya Charles
+8 more
Zufan Debebe
Victor R. Gordeuk
Marina Jerebtsova
Joseph Kurantsin-Mills
Sergei Nekhai
Xiaomei Niu
Patricio E. Ray
Des R. Richardson
Publication date
25 October 2007
Publisher
Digital Howard @ Howard University
Doi
Cite
View
on
PubMed
Abstract
HIV-1 replication is induced by an excess of iron and iron chelation by desferrioxamine (DFO) inhibits viral replication by reducing proliferation of infected cells. Treatment of cells with DFO and 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (311) inhibit expression of proteins that regulate cell-cycle progression, including cycle-dependent kinase 2 (CDK2). Our recent studies showed that CDK2 participates in HIV-1 transcription and viral replication suggesting that inhibition of CDK2 by iron chelators might also affect HIV-1 transcription. Here we evaluated the effect of a clinically approved orally effective iron chelator, 4-[3,5-bis-(hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid (ICL670) and 311 on HIV-1 transcription. Both ICL670 and 311 inhibited Tat-induced HIV-1 transcription in CEM-T cells, 293T and HeLa cells. Neither ICL670 nor 311 induced cytotoxicity at concentrations that inhibited HIV-1 transcription. The chelators decreased cellular activity of CDK2 and reduced HIV-1 Tat phosphorylation by CDK2. Neither ICL670A or 311 decreased CDK9 protein level but significantly reduced association of CDK9 with cyclin T1 and reduced phosphorylation of Ser-2 residues of RNA polymerase II C-terminal domain. In conclusion, our findings add to the evidence that iron chelators can inhibit HIV-1 transcription by deregulating CDK2 and CDK9. Further consideration should be given to the development of iron chelators for future anti-retroviral therapeutics. © 2007 Elsevier Inc. All rights reserved
Similar works
Full text
Available Versions
Elsevier - Publisher Connector
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 05/06/2019
Howard University: Digital Howard
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:dh.howard.edu:sicklecell_f...
Last time updated on 16/12/2021